CytoSorb in Patients With Liver Failure

Effects of Renal Replacement Therapy With Hemoadsoption in Patients With Liver Failure

Status

Completed

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04511507

Enrollment

Registered

2020-08-13

Start date

2016-02-10

Completion date

2021-08-30

Last updated

2021-09-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver Dysfunction

Brief summary

Hemoadsorption has been demonstrated to improve liver functional tests in patients with liver failure. The present study investigates the effects of three consecutive sessions of hemoadsorption, performed in accordance to the local protocol for treating patients with acute liver failure, on liver functional tests, severity scores and 30-days mortality. Paraclinical results and severity scores were obtained before and after the three consecutive sessions.

Interventions

PROCEDUREhemoadsorption

three consecutive sessions of hemoadsorption in patients with liver failure

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* patients with acute liver failure or acute on chronic liver failure who require hemoadsorption in accordance with local guidelines

Exclusion criteria

* unsigned informed consent * duration of therapy under 12 hours * death before the three consecutive sessions

Design outcomes

Primary

Measure	Time frame	Description
30 days mortality	30 days	30 days mortality

Countries

Romania

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026